# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary...
Wedbush analyst Laura Chico initiates coverage on Catabasis Pharmaceuticals (NASDAQ:CATB) with a Outperform rating and annou...
Before 10 a.m. ET on Wednesday, 124 companies hit new 52-week highs.
HC Wainwright & Co. analyst Joseph Pantginis upgrades Catabasis Pharmaceuticals (NASDAQ:CATB) from Neutral to Buy and an...
Gainers Trillium Therapeutics Inc. (NASDAQ: TRIL) shares jumped 188.8% to close at $17.59 on Monday after the company agreed...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitti...